Monoclonal Antibodies Market Expected to Reach $390.58 Billion by 2030

According to a new report published by Allied Market Research, titled, “Monoclonal Antibodies Market by Source, Indication, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global monoclonal antibodies market was valued at $146,642 million in 2020, and is projected to reach $390,582 million by 2030, registering a CAGR of 10.2% from 2021 to 2030.

Monoclonal antibodies result from single type of immune cell, each a clone of single parent cell. These monoclonal antibodies are utilized in immunotherapy for the treatment of several chronic diseases such as Multiple sclerosis, cancer, cardiovascular diseases, and other. Monoclonal antibodies inhibit & target with exploit of a receptor that is involved in the development of the disease that is being treated. The monoclonal antibodies are developed from sources such as murine, chimeric, humanized, and human.

Rise in prevalence of cancer and other chronic diseases, increase in R&D activities in genomics along with surge in demand for technologically advanced genetic platforms, and rise in patient awareness toward applications of monoclonal antibodies (mAb) therapy are the major factors that boost the growth of the market. In addition, increase in number of initiatives and enhanced investments from governments for the overall R&D of monoclonal antibodies, rise in number of product approvals, surge in demand for personalized medicine, and increase in number of pharmaceutical & biopharmaceutical companies are other factors that further drive the growth of the market. However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. From 2020, five monoclonal antibodies (mAbs) been developed and got an Emergency Use Authorization (EUA) by the U.S. and South Korea regulatory agencies for the treatment of COVID-19. Moreover, several additional regulatory agencies are evaluating monoclonal antibodies in phase 3 clinical trials or currently looking for a EUA. Monoclonal antibodies (mAbs) in development for COVID-19 were discovered from SARS-CoV-immune donors (VIR-7831 and ADG2), SARS-CoV-2-immune donors, and wild-type mice (ABBV-2B04) or immunized humanized immunoglobulin mice (REGN10933 & ABBV-47D11).  Thus, increase in demand for monoclonal antibodies therapeutics against COVID-19 is anticipated to drive the monoclonal antibodies market during the forecast period.

The monoclonal antibodies market is segmented on the basis of source, indication, end user, and region.

On the basis of source, the market is categorized into murine, chimeric, humanized, and human. The human segment dominated the global monoclonal antibodies market in 2020, and is anticipated to continue this trend during the forecast period. Key factors, such as increase in government support in infection control & management, and increase in number of product approvals, drive the growth of the market. In addition, employment of advanced genetic engineering technology, rise in integration of advanced technology such as phage or yeast display, and transgenic mice for humanized monoclonal antibodies generation, and increase in usage of monoclonal antibodies for treatment of various chronic diseases further drive the growth of the monoclonal antibodies market.

By indication, the market is divided into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others. The cancer segment is anticipated to depict significant growth during the forecast period due to increase in prevalence of cancer, surge in number of drug pipelines, rise in adoption of monoclonal antibodies in cancer treatment, increase in awareness level amongst the patient population regarding cancer treatment procedures, and surge in demand for biosimilar monoclonal antibodies.

KEY FINDINGS OF THE STUDY 

• Based on source, the human segment held the largest market share in 2020, and is expected to remain dominant during the forecast period. 
• On the basis of indication, the cancer segment held the largest market share in 2020, and is expected to remain dominant during the forecast period.   
• On the basis of end user, the hospitals segment held the largest market share in 2020, and is expected to remain dominant during the forecast period.  
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 11.7% during the forecast period. 

In 2020, North America accounted for a major share in the monoclonal antibodies market, owing to rise in awareness levels among patients & physicians pertaining to the applications of monoclonal antibodies (mAb) therapy, and increase in approval of blockbuster mAbs for a variety of applications. However, Asia-Pacific is projected to register the fastest growth rate during the forecast period, owing to increase in research on biomedical and regenerative medicine, increase in awareness related to monoclonal antibodies, and availability of trained medical professionals.